APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector and Plasmid DNA

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Selected research

Market Outlook & Growth Opportunities

Global Viral Vector and Plasmid DNA Market Outlook and Growth Opportunities 2026

28 December 2025210 pages

Choose your research edition.

Industry ResearchViral Vector and Plasmid DNA Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector and Plasmid DNA Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Viral Vector and Plasmid DNA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector and Plasmid DNA Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vector and Plasmid DNA Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.

North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.

Read the full market overview

In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.

This report provides an overview of the global Viral Vector and Plasmid DNA market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vector and Plasmid DNA and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vector and Plasmid DNA revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Vector and Plasmid DNA market.

Viral Vector and Plasmid DNA Segment by Company

Brammer Bio

Oxford BioMedica

Cobra Biologics

FinVector

Lonza

BioReliance

MolMed

FUJIFILM Diosynth Biotechnologies

UniQure

Aldevron

Richter-Helm

Eurogentec

OBiO Technology

Yposkesi

Cell and Gene Therapy Catapult

MassBiologics

Biovian

VGXI

Gene Synthesis

PlasmidFactory

Jikai Gene

Viral Vector and Plasmid DNA Segment by Type

Plasmid DNA

Viral Vector

Viral Vector and Plasmid DNA Segment by Application

Cancer

Virus Infection

Hereditary Disease

Viral Vector and Plasmid DNA Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viral Vector and Plasmid DNA status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Viral Vector and Plasmid DNA key companies, revenue, market share, and recent developments.

3. To split the Viral Vector and Plasmid DNA breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Viral Vector and Plasmid DNA market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viral Vector and Plasmid DNA significant trends, drivers, influence factors in global and regions.

6. To analyze Viral Vector and Plasmid DNA competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector and Plasmid DNA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector and Plasmid DNA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector and Plasmid DNA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vector and Plasmid DNA industry.

Chapter 3: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Viral Vector and Plasmid DNA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Viral Vector and Plasmid DNA in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viral Vector and Plasmid DNA Industry Trends Table 2. Viral Vector and Plasmid DNA Industry Drivers Table 3. Viral Vector and Plasmid DNA Industry Opportunities and Challenges Table 4. Viral Vector and Plasmid DNA Industry Restraints Table 5. Global Viral Vector and Plasmid DNA Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viral Vector and Plasmid DNA Revenue Share by Company (2021-2026) Table 7. Global Viral Vector and Plasmid DNA Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Viral Vector and Plasmid DNA Key Company Manufacturing Base & Headquarters Table 9. Global Viral Vector and Plasmid DNA Company, Product Type & Application Table 10. Global Viral Vector and Plasmid DNA Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Viral Vector and Plasmid DNA by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Plasmid DNA Table 15. Significant Companies of Viral Vector Table 16. Global Viral Vector and Plasmid DNA Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Viral Vector and Plasmid DNA Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Viral Vector and Plasmid DNA Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Viral Vector and Plasmid DNA Sales Value Share by Type (2021-2026) Table 20. Global Viral Vector and Plasmid DNA Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Virus Infection Table 23. Significant Companies of Hereditary Disease Table 24. Global Viral Vector and Plasmid DNA Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Viral Vector and Plasmid DNA Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Viral Vector and Plasmid DNA Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Viral Vector and Plasmid DNA Sales Value Share by Application (2021-2026) Table 28. Global Viral Vector and Plasmid DNA Sales Value Share by Application (2027-2032) Table 29. Global Viral Vector and Plasmid DNA Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Viral Vector and Plasmid DNA Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Viral Vector and Plasmid DNA Sales Value Share by Region (2021-2026) Table 32. Global Viral Vector and Plasmid DNA Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Viral Vector and Plasmid DNA Sales Value Share by Region (2027-2032) Table 34. Global Viral Vector and Plasmid DNA Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Viral Vector and Plasmid DNA Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Viral Vector and Plasmid DNA Sales Value Market Share by Country (2021-2026) Table 37. Global Viral Vector and Plasmid DNA Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Viral Vector and Plasmid DNA Sales Value Market Share by Country (2027-2032) Table 39. Brammer Bio Company Information Table 40. Brammer Bio Business Overview Table 41. Brammer Bio Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Brammer Bio Viral Vector and Plasmid DNA Product Portfolio Table 43. Brammer Bio Recent Development Table 44. Oxford BioMedica Company Information Table 45. Oxford BioMedica Business Overview Table 46. Oxford BioMedica Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio Table 48. Oxford BioMedica Recent Development Table 49. Cobra Biologics Company Information Table 50. Cobra Biologics Business Overview Table 51. Cobra Biologics Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio Table 53. Cobra Biologics Recent Development Table 54. FinVector Company Information Table 55. FinVector Business Overview Table 56. FinVector Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. FinVector Viral Vector and Plasmid DNA Product Portfolio Table 58. FinVector Recent Development Table 59. Lonza Company Information Table 60. Lonza Business Overview Table 61. Lonza Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Lonza Viral Vector and Plasmid DNA Product Portfolio Table 63. Lonza Recent Development Table 64. BioReliance Company Information Table 65. BioReliance Business Overview Table 66. BioReliance Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. BioReliance Viral Vector and Plasmid DNA Product Portfolio Table 68. BioReliance Recent Development Table 69. MolMed Company Information Table 70. MolMed Business Overview Table 71. MolMed Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. MolMed Viral Vector and Plasmid DNA Product Portfolio Table 73. MolMed Recent Development Table 74. FUJIFILM Diosynth Biotechnologies Company Information Table 75. FUJIFILM Diosynth Biotechnologies Business Overview Table 76. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio Table 78. FUJIFILM Diosynth Biotechnologies Recent Development Table 79. UniQure Company Information Table 80. UniQure Business Overview Table 81. UniQure Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. UniQure Viral Vector and Plasmid DNA Product Portfolio Table 83. UniQure Recent Development Table 84. Aldevron Company Information Table 85. Aldevron Business Overview Table 86. Aldevron Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Aldevron Viral Vector and Plasmid DNA Product Portfolio Table 88. Aldevron Recent Development Table 89. Richter-Helm Company Information Table 90. Richter-Helm Business Overview Table 91. Richter-Helm Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Richter-Helm Viral Vector and Plasmid DNA Product Portfolio Table 93. Richter-Helm Recent Development Table 94. Eurogentec Company Information Table 95. Eurogentec Business Overview Table 96. Eurogentec Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Eurogentec Viral Vector and Plasmid DNA Product Portfolio Table 98. Eurogentec Recent Development Table 99. OBiO Technology Company Information Table 100. OBiO Technology Business Overview Table 101. OBiO Technology Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. OBiO Technology Viral Vector and Plasmid DNA Product Portfolio Table 103. OBiO Technology Recent Development Table 104. Yposkesi Company Information Table 105. Yposkesi Business Overview Table 106. Yposkesi Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Yposkesi Viral Vector and Plasmid DNA Product Portfolio Table 108. Yposkesi Recent Development Table 109. Cell and Gene Therapy Catapult Company Information Table 110. Cell and Gene Therapy Catapult Business Overview Table 111. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio Table 113. Cell and Gene Therapy Catapult Recent Development Table 114. MassBiologics Company Information Table 115. MassBiologics Business Overview Table 116. MassBiologics Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. MassBiologics Viral Vector and Plasmid DNA Product Portfolio Table 118. MassBiologics Recent Development Table 119. Biovian Company Information Table 120. Biovian Business Overview Table 121. Biovian Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Biovian Viral Vector and Plasmid DNA Product Portfolio Table 123. Biovian Recent Development Table 124. VGXI Company Information Table 125. VGXI Business Overview Table 126. VGXI Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. VGXI Viral Vector and Plasmid DNA Product Portfolio Table 128. VGXI Recent Development Table 129. Gene Synthesis Company Information Table 130. Gene Synthesis Business Overview Table 131. Gene Synthesis Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio Table 133. Gene Synthesis Recent Development Table 134. PlasmidFactory Company Information Table 135. PlasmidFactory Business Overview Table 136. PlasmidFactory Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio Table 138. PlasmidFactory Recent Development Table 139. Jikai Gene Company Information Table 140. Jikai Gene Business Overview Table 141. Jikai Gene Viral Vector and Plasmid DNA Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Jikai Gene Viral Vector and Plasmid DNA Product Portfolio Table 143. Jikai Gene Recent Development Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Viral Vector and Plasmid DNA Product Image Figure 2. Global Viral Vector and Plasmid DNA Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vector and Plasmid DNA Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Vector and Plasmid DNA Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Plasmid DNA Image Figure 8. Viral Vector Image Figure 9. Global Viral Vector and Plasmid DNA Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Viral Vector and Plasmid DNA Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Viral Vector and Plasmid DNA Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Virus Infection Image Figure 14. Hereditary Disease Image Figure 15. Global Viral Vector and Plasmid DNA Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Viral Vector and Plasmid DNA Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Viral Vector and Plasmid DNA Sales Value Share by Application (2021-2032) Figure 18. Global Viral Vector and Plasmid DNA Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Viral Vector and Plasmid DNA Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Viral Vector and Plasmid DNA Sales Value (2021-2032) & (US$ Million) Figure 21. North America Viral Vector and Plasmid DNA Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Viral Vector and Plasmid DNA Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Viral Vector and Plasmid DNA Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Viral Vector and Plasmid DNA Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Viral Vector and Plasmid DNA Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Viral Vector and Plasmid DNA Sales Value (2021-2032) & (US$ Million) Figure 27. South America Viral Vector and Plasmid DNA Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Viral Vector and Plasmid DNA Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Viral Vector and Plasmid DNA Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Plasmid DNA
  • Viral Vector
Applications
  • Cancer
  • Virus Infection
  • Hereditary Disease
Companies covered
  • Brammer Bio
  • Oxford BioMedica
  • Cobra Biologics
  • FinVector
  • Lonza
  • BioReliance
  • MolMed
  • FUJIFILM Diosynth Biotechnologies
  • UniQure
  • Aldevron
  • Richter-Helm
  • Eurogentec
  • OBiO Technology
  • Yposkesi
  • Cell and Gene Therapy Catapult
  • MassBiologics
  • Biovian
  • VGXI
  • Gene Synthesis
  • PlasmidFactory
  • Jikai Gene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Viral Vector and Plasmid DNA Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Viral Vector and Plasmid DNA Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Viral Vector and Plasmid DNA Market Dynamics
  1. 2.1 Viral Vector and Plasmid DNA Industry Trends
  2. 2.2 Viral Vector and Plasmid DNA Industry Drivers
  3. 2.3 Viral Vector and Plasmid DNA Industry Opportunities and Challenges
  4. 2.4 Viral Vector and Plasmid DNA Industry Restraints
3 Viral Vector and Plasmid DNA Market by Company
  1. 3.1 Global Viral Vector and Plasmid DNA Company Revenue Ranking in 2025
  2. 3.2 Global Viral Vector and Plasmid DNA Revenue by Company (2021-2026)
  3. 3.3 Global Viral Vector and Plasmid DNA Company Ranking (2024-2026)
  4. 3.4 Global Viral Vector and Plasmid DNA Company Manufacturing Base and Headquarters
  5. 3.5 Global Viral Vector and Plasmid DNA Company Product Type and Application
  6. 3.6 Global Viral Vector and Plasmid DNA Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Viral Vector and Plasmid DNA Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Viral Vector and Plasmid DNA Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Viral Vector and Plasmid DNA Market by Type
  1. 4.1 Viral Vector and Plasmid DNA Type Introduction
  2. 4.1.1 Plasmid DNA
  3. 4.1.2 Viral Vector
  4. 4.2 Global Viral Vector and Plasmid DNA Sales Value by Type
  5. 4.2.1 Global Viral Vector and Plasmid DNA Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Viral Vector and Plasmid DNA Sales Value by Type (2021-2032)
  7. 4.2.3 Global Viral Vector and Plasmid DNA Sales Value Share by Type (2021-2032)
5 Viral Vector and Plasmid DNA Market by Application
  1. 5.1 Viral Vector and Plasmid DNA Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Virus Infection
  4. 5.1.3 Hereditary Disease
  5. 5.2 Global Viral Vector and Plasmid DNA Sales Value by Application
  6. 5.2.1 Global Viral Vector and Plasmid DNA Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Viral Vector and Plasmid DNA Sales Value by Application (2021-2032)
  8. 5.2.3 Global Viral Vector and Plasmid DNA Sales Value Share by Application (2021-2032)
6 Viral Vector and Plasmid DNA Regional Value Analysis
  1. 6.1 Global Viral Vector and Plasmid DNA Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Vector and Plasmid DNA Sales Value by Region (2021-2032)
  3. 6.2.1 Global Viral Vector and Plasmid DNA Sales Value by Region: 2021-2026
  4. 6.2.2 Global Viral Vector and Plasmid DNA Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Viral Vector and Plasmid DNA Sales Value (2021-2032)
  7. 6.3.2 North America Viral Vector and Plasmid DNA Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Viral Vector and Plasmid DNA Sales Value (2021-2032)
  10. 6.4.2 Europe Viral Vector and Plasmid DNA Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Viral Vector and Plasmid DNA Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Viral Vector and Plasmid DNA Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Viral Vector and Plasmid DNA Sales Value (2021-2032)
  16. 6.6.2 South America Viral Vector and Plasmid DNA Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Viral Vector and Plasmid DNA Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Viral Vector and Plasmid DNA Sales Value Share by Country, 2025 VS 2032
7 Viral Vector and Plasmid DNA Country-level Value Analysis
  1. 7.1 Global Viral Vector and Plasmid DNA Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viral Vector and Plasmid DNA Sales Value by Country (2021-2032)
  3. 7.2.1 Global Viral Vector and Plasmid DNA Sales Value by Country (2021-2026)
  4. 7.2.2 Global Viral Vector and Plasmid DNA Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Viral Vector and Plasmid DNA Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Viral Vector and Plasmid DNA Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Viral Vector and Plasmid DNA Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Brammer Bio
  2. 8.1.1 Brammer Bio Company Information
  3. 8.1.2 Brammer Bio Business Overview
  4. 8.1.3 Brammer Bio Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Brammer Bio Viral Vector and Plasmid DNA Product Portfolio
  6. 8.1.5 Brammer Bio Recent Developments
  7. 8.2 Oxford BioMedica
  8. 8.2.1 Oxford BioMedica Company Information
  9. 8.2.2 Oxford BioMedica Business Overview
  10. 8.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio
  12. 8.2.5 Oxford BioMedica Recent Developments
  13. 8.3 Cobra Biologics
  14. 8.3.1 Cobra Biologics Company Information
  15. 8.3.2 Cobra Biologics Business Overview
  16. 8.3.3 Cobra Biologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio
  18. 8.3.5 Cobra Biologics Recent Developments
  19. 8.4 FinVector
  20. 8.4.1 FinVector Company Information
  21. 8.4.2 FinVector Business Overview
  22. 8.4.3 FinVector Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  23. 8.4.4 FinVector Viral Vector and Plasmid DNA Product Portfolio
  24. 8.4.5 FinVector Recent Developments
  25. 8.5 Lonza
  26. 8.5.1 Lonza Company Information
  27. 8.5.2 Lonza Business Overview
  28. 8.5.3 Lonza Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lonza Viral Vector and Plasmid DNA Product Portfolio
  30. 8.5.5 Lonza Recent Developments
  31. 8.6 BioReliance
  32. 8.6.1 BioReliance Company Information
  33. 8.6.2 BioReliance Business Overview
  34. 8.6.3 BioReliance Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BioReliance Viral Vector and Plasmid DNA Product Portfolio
  36. 8.6.5 BioReliance Recent Developments
  37. 8.7 MolMed
  38. 8.7.1 MolMed Company Information
  39. 8.7.2 MolMed Business Overview
  40. 8.7.3 MolMed Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MolMed Viral Vector and Plasmid DNA Product Portfolio
  42. 8.7.5 MolMed Recent Developments
  43. 8.8 FUJIFILM Diosynth Biotechnologies
  44. 8.8.1 FUJIFILM Diosynth Biotechnologies Company Information
  45. 8.8.2 FUJIFILM Diosynth Biotechnologies Business Overview
  46. 8.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  47. 8.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio
  48. 8.8.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  49. 8.9 UniQure
  50. 8.9.1 UniQure Company Information
  51. 8.9.2 UniQure Business Overview
  52. 8.9.3 UniQure Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  53. 8.9.4 UniQure Viral Vector and Plasmid DNA Product Portfolio
  54. 8.9.5 UniQure Recent Developments
  55. 8.10 Aldevron
  56. 8.10.1 Aldevron Company Information
  57. 8.10.2 Aldevron Business Overview
  58. 8.10.3 Aldevron Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aldevron Viral Vector and Plasmid DNA Product Portfolio
  60. 8.10.5 Aldevron Recent Developments
  61. 8.11 Richter-Helm
  62. 8.11.1 Richter-Helm Company Information
  63. 8.11.2 Richter-Helm Business Overview
  64. 8.11.3 Richter-Helm Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Richter-Helm Viral Vector and Plasmid DNA Product Portfolio
  66. 8.11.5 Richter-Helm Recent Developments
  67. 8.12 Eurogentec
  68. 8.12.1 Eurogentec Company Information
  69. 8.12.2 Eurogentec Business Overview
  70. 8.12.3 Eurogentec Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eurogentec Viral Vector and Plasmid DNA Product Portfolio
  72. 8.12.5 Eurogentec Recent Developments
  73. 8.13 OBiO Technology
  74. 8.13.1 OBiO Technology Company Information
  75. 8.13.2 OBiO Technology Business Overview
  76. 8.13.3 OBiO Technology Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  77. 8.13.4 OBiO Technology Viral Vector and Plasmid DNA Product Portfolio
  78. 8.13.5 OBiO Technology Recent Developments
  79. 8.14 Yposkesi
  80. 8.14.1 Yposkesi Company Information
  81. 8.14.2 Yposkesi Business Overview
  82. 8.14.3 Yposkesi Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Yposkesi Viral Vector and Plasmid DNA Product Portfolio
  84. 8.14.5 Yposkesi Recent Developments
  85. 8.15 Cell and Gene Therapy Catapult
  86. 8.15.1 Cell and Gene Therapy Catapult Company Information
  87. 8.15.2 Cell and Gene Therapy Catapult Business Overview
  88. 8.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio
  90. 8.15.5 Cell and Gene Therapy Catapult Recent Developments
  91. 8.16 MassBiologics
  92. 8.16.1 MassBiologics Company Information
  93. 8.16.2 MassBiologics Business Overview
  94. 8.16.3 MassBiologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  95. 8.16.4 MassBiologics Viral Vector and Plasmid DNA Product Portfolio
  96. 8.16.5 MassBiologics Recent Developments
  97. 8.17 Biovian
  98. 8.17.1 Biovian Company Information
  99. 8.17.2 Biovian Business Overview
  100. 8.17.3 Biovian Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biovian Viral Vector and Plasmid DNA Product Portfolio
  102. 8.17.5 Biovian Recent Developments
  103. 8.18 VGXI
  104. 8.18.1 VGXI Company Information
  105. 8.18.2 VGXI Business Overview
  106. 8.18.3 VGXI Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  107. 8.18.4 VGXI Viral Vector and Plasmid DNA Product Portfolio
  108. 8.18.5 VGXI Recent Developments
  109. 8.19 Gene Synthesis
  110. 8.19.1 Gene Synthesis Company Information
  111. 8.19.2 Gene Synthesis Business Overview
  112. 8.19.3 Gene Synthesis Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio
  114. 8.19.5 Gene Synthesis Recent Developments
  115. 8.20 PlasmidFactory
  116. 8.20.1 PlasmidFactory Company Information
  117. 8.20.2 PlasmidFactory Business Overview
  118. 8.20.3 PlasmidFactory Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  119. 8.20.4 PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio
  120. 8.20.5 PlasmidFactory Recent Developments
  121. 8.21 Jikai Gene
  122. 8.21.1 Jikai Gene Company Information
  123. 8.21.2 Jikai Gene Business Overview
  124. 8.21.3 Jikai Gene Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Jikai Gene Viral Vector and Plasmid DNA Product Portfolio
  126. 8.21.5 Jikai Gene Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst